BMT CTN Protocol 1102

A Multi-Center Biologic Assignment Trial Comparing Reduced Intensity Allogeneic Hematopoietic Cell Transplant to Hypomethylating Therapy or Best Supportive Care in Patients Aged 50-75 with Intermediate-2 and High Risk Myelodysplastic Syndrome.

Below are protocol-related documents, which may be periodically updated.

            Protocol Co-Chair: Ryotaro Nakamura, MD (626-256-4673) rnakamura@coh.org

            Protocol Co-Chair: Corey Cutler,MD () cscutler@partners.org

            Protocol Officer: Wael Saber, MD414-805-0300) wsaber@mcw.edu

            Protocol Coordinator: Alyssa Ramirez (301-251-1161) aramirez@emmes.com

            Medical Monitor: Bipin Savini, MD bipin.savini@vanderbilt.edu

                   

The BMT CTN is committed to including widespread transplant community participation in these trials. However, affiliate center applications are not currently being accepted for this study.